Switching exenatide or gliptins to liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit

K.Y. Thong¹, K. Darzy², M.L. Cull¹, A.P. Mills¹, R.E.J. Ryder¹, ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Diabetes, Birmingham, UK

²Queen Elizabeth II Hospital, Diabetes, Welwyn Garden City, UK

Factors associated with HbA1c and weight changes in the Association of British Clinical Diabetologists (ABCD) nationwide GLP-1 agonists audit

K.Y. Thong¹, R.E.J. Ryder¹, C. Walton², ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Diabetes, Birmingham, UK

²Hull Royal Infirmary, Diabetes, Hull, UK

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton², ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, City Hospital, Birmingham, UK

²Diabetes, Hull Royal Infirmary, Hull, UK

Factors associated with HbA1c and weight changes at 6 months in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audit

C. Walton¹, R.E.J. Ryder², M.L. Cull², A.P. Mills², K.Y. Thong², ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, Hull Royal Infirmary, Hull, UK

²Diabetes, City Hospital, Birmingham, UK

Factors associated with HbA1c and Weight changes at 6 months in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audit

C. Walton¹, R.E.J. Ryder², M.L. Cull², A.P. Mills², K.Y. Thong², ABCD nationwide exenatide and liraglutide audit contributors;

¹Diabetes, Hull Royal Infirmary, Hull, UK

²Diabetes, City Hospital, Birmingham, UK

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹,  A.P. Mills¹, C. Walton², ABCD nationwide exenatide and liraglutide audit contributors;

¹Diabetes, City Hospital, Birmingham, UK

²Diabetes, Hull Royal Infirmary, Hull, UK

Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine). Diabetologia 2018, Vol.61 Supplement1: Abstract 747

C. Walton¹, S. Kassim², R. Harper³, P. McDonald³, U. Brennan³, J. Harding³, T. Htay⁴, R. Nayar⁵, A. Pernet⁶, S. Rowles⁷, K. Adamson⁸, K.Y. Thong⁹, R.E.J. Ryder¹⁰

¹Hull Royal Infirmary, Hull, UK

This template is based on the NHS ‘Clinical guide for the management of acute diabetes during the coronavirus pandemic’ ref 001559. The body of the document has been retained but space has been provided for you to populate to describe your local arrangements. In addition to the ‘blank’ template we have provided a specimen example which may be helpful. Clearly, arrangements will be different for different services and will depend on staff levels.  
We hope you will find this useful in planning diabetes services in the light of the existing NHS guidance.     

The aim of this document is to provide some detail on how maintenance of a level of specialist diabetes service can be achieved during COVID-19

Updated November 2020